Juno Therapeutics Inc (NASDAQ:JUNO)’s share price dropped 1.3% during trading on Monday . The company traded as low as $28.42 and last traded at $28.84, with a volume of 1,199,339 shares traded. The stock had previously closed at $29.21.

JUNO has been the subject of a number of research analyst reports. Morgan Stanley lifted their price objective on shares of Juno Therapeutics from $48.00 to $50.00 in a research report on Friday, April 8th. FBR & Co reissued a “buy” rating and set a $73.00 target price on shares of Juno Therapeutics in a report on Saturday, April 9th. Maxim Group reissued a “buy” rating and set a $80.00 target price (up previously from $78.00) on shares of Juno Therapeutics in a report on Monday, April 11th. Zacks Investment Research downgraded Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, April 15th. Finally, SunTrust Banks Inc. reissued a “buy” rating and set a $50.00 target price on shares of Juno Therapeutics in a report on Wednesday, April 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Juno Therapeutics has a consensus rating of “Buy” and an average target price of $54.84.

The firm’s market capitalization is $2.87 billion. The company has a 50-day moving average of $39.26 and a 200 day moving average of $37.74.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.26. The business earned $9.80 million during the quarter, compared to analysts’ expectations of $4.83 million. During the same period in the previous year, the business earned ($0.30) EPS. On average, analysts forecast that Juno Therapeutics Inc will post ($2.28) EPS for the current year.

In other news, Director Richard Klausner sold 12,000 shares of the stock in a transaction on Friday, June 24th. The stock was sold at an average price of $40.71, for a total transaction of $488,520.00. Following the completion of the transaction, the director now owns 846,799 shares in the company, valued at approximately $34,473,187.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Hans Edgar Bishop sold 90,750 shares of the stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $46.42, for a total value of $4,212,615.00. Following the transaction, the chief executive officer now owns 2,704,609 shares of the company’s stock, valued at approximately $125,547,949.78. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently bought and sold shares of the company. BBR Partners LLC purchased a new position in Juno Therapeutics during the fourth quarter valued at $1,539,000. BNP Paribas Arbitrage SA increased its position in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares during the last quarter. Swiss National Bank purchased a new position in Juno Therapeutics during the fourth quarter valued at $2,603,000. ProShare Advisors LLC purchased a new position in Juno Therapeutics during the fourth quarter valued at $3,674,000. Finally, US Bancorp DE increased its position in shares of Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock valued at $3,900,000 after buying an additional 1,600 shares in the last quarter.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.